A reading of the reports suggests that there is no standard practice for reporting political contributions and it is left to the company's discretion to report them as they find fit. Illustration:......
The Central Drugs Standard Control Organisation has granted restricted emergency use authorisation to two new vaccines and a drug for COVID-19, taking the number of preventives and treatments......
Government institutions and pharma industry are examining if a 'cocktail' approach to making a multi-variant Covid-19 vaccine works against multiple strains of the ever-mutating virus,......
Trials for Bharat Biotech's Covid-19 vaccine Covaxin on children are underway and results are expected to be released by September, All India Institute of Medical Sciences director Randeep Guleria......
India is expecting 156 million doses of the vaccine from August to September, reports Ruchika Chitravanshi. Photograph: Kind courtesy Russian Direct Investment Fund on Facebook Sputnik V, the......
Notwithstanding the fact that the country’s pharmaceutical (pharma) pricing regulator has allowed a 12 per cent price increase for medicines listed under the National List of Essential......
An acute drug shortage in the US and stable pricing along with product launches are likely to boost revenues of India’s pharmaceutical companies during the first quarter of this financial......
Healthcare stocks have outperformed the benchmark indices since the start of the current financial year. Illustration: Uttam Ghosh/Rediff.com The BSE Healthcare Index is up 19 per cent as compared......
Drug shortages in the US are at an all-time high, and price erosion has stabilised, which could benefit Indian pharmaceutical (pharma) companies with a US focus, according to analysts. Image used......
Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels. Illustration: Uttam Ghosh/Rediff.com Analysts feel that revenue and EBIDTA growth in the pharmaceutical sector......